See where youcan take the test
Offer EarlyCDT-Lung to your Patients
Assess lung cancer risk
Health Diagnostic Laboratory, Inc. has acquired substantially all of the assets of Oncimmune USA LLC, the subsidiary of Oncimmune Ltd.
CLICK HERE FOR PRESS RELEASE
Oncimmune has established a Science Committee to lead and approve all of the workflow of the Company’s R&D department, ensuring that all research is clearly focused on the interests of the Company.
CLICK HERE FOR COMPANY STATEMENT
Professor Robertson has ceased to be a director and Chief Scientific Officer of Oncimmune Limited by mutual agreement with effect from 30 October 2013.
Find lung cancer before symptoms appear. EarlyCDT-Lung combined with CT can help.
Panel of autoantibodies to aid in early lung cancer detection
Recent NLST Trial further shows 20% mortality improvement. EarlyCDT-Lung can reduce false positives associated with CT.
How to identify the relatively small percentage of lung cancers (5-50 depending on the level of risk), per 1,000, that are present in your high-risk patient population. More….
Use of EarlyCDT-Lung:
EarlyCDT-Lung is a simple blood test which is ordered by a GP, or other suitably qualified medical professional, to aid in the risk assessment and early detection of lung cancer. More…
© 2013 Oncimmune Limited | Clinical Sciences Building | Nottingham City Hospital | Hucknall Rd. | Nottingham NG5 1PB | +44 (0) 115 82 31869